Skip to main content

View full-text article in PMC

. 2023 Jan 1;20(1):94–101. doi: 10.1513/AnnalsATS.202205-403OC

Table 2.

Rate and adjusted odds of receiving midazolam, dexmedetomidine, and ketamine in the primary and MIMIC-IV cohorts

Sedative Agent	Primary Cohort		MIMIC-IV
Sedative Agent	%	aOR (95% CI)	%	aOR (95% CI)
Midazolam infusion
High triglyceride (>400 mg/dl)	37.0	3.1 (2.2–4.4)	55.0	3.6 (2.4–5.5)
Low triglyceride (⩽400 mg/dl)	16.4	3.1 (2.2–4.4)	27.2	3.6 (2.4–5.5)
Dexmedetomidine
High triglyceride (>400 mg/dl)	57.7	1.5 (1.1–1.9)	72.3	1.3 (0.9–1.9)
Low triglyceride (⩽400 mg/dl)	46.6	1.5 (1.1–1.9)	51.8	1.3 (0.9–1.9)
Ketamine infusion
High triglyceride (>400 mg/dl)	22.8	2.3 (2.3–5.3)	5.0	0.1 (0.0–0.8)
Low triglyceride (⩽400 mg/dl)	6.9	2.3 (2.3–5.3)	2.2	0.1 (0.0–0.8)

Definition of abbreviations: aOR = adjusted odds ratio; CI = confidence interval; MIMIC-IV = Medical Information Mart for Intensive Care-IV.